U.S. Markets open in 9 hrs 20 mins

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
73.20+0.42 (+0.58%)
At close: 4:00PM EDT
People also watch
PODDNUVAABMDELGXEW

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858-200-0200
http://www.dexcom.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees1,900

Key Executives

NameTitlePayExercisedAge
Mr. Kevin R. SayerChief Exec. Officer, Pres and Director1.08M1.64M59
Mr. Steven R. PacelliExec. VP of Strategy & Corp. Devel.613.34k31745
Mr. Richard B. DoubledayChief Commercial Officer and Exec. VP613.34kN/A54
Mr. Donald M. AbbeyExec. VP of Quality & Information Technology380.73kN/A50
Mr. Terrance H. GreggExec. ChairmanN/AN/A68
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.